Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Neurodegenerative disease stories

Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Nov 2, 2026

FDA sets May 2027 review date for uniQure's Huntington's gene therapy

The FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.

Nov 2, 2026·2 sources
00
Oct 30, 2026

First patient receives Sumitomo Pharma stem cell transplant for Parkinson's disease

A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.

Oct 30, 2026·3 sources
00
Oct 29, 2026

Sutter Health review board improves access to anti-amyloid Alzheimer's therapies

Sutter Health has implemented a review board system to more efficiently process referrals for anti-amyloid therapies that slow Alzheimer's disease progression, as demand for these treatments increases. The approach aims to streamline access to these disease-modifying treatments for eligible patients.

Oct 29, 2026·2 sources
00

International study identifies 127 genetic risk regions for Alzheimer's disease

A large-scale multi-ancestry genetic study led by Ole Andreassen at University of Oslo has identified new DNA risk factors for Alzheimer's disease, implicating microglial and neuronal dysregulation. The research reveals a larger common-variant contribution to the disease than previously estimated and identifies potential new drug targets.

Oct 29, 2026·3 sources
00
Oct 14, 2026

Arrowhead Pharmaceuticals' ARO-MAPT shows first evidence of tau protein reduction in Alzheimer's trial

Arrowhead Pharmaceuticals reported interim Phase 1/2a results showing its experimental RNA interference drug ARO-MAPT successfully crossed the blood-brain barrier and reduced levels of tau protein, a key marker implicated in Alzheimer's disease. The subcutaneously administered treatment represents the first RNAi medicine to achieve this effect in the brain, with analysts describing the magnitude of tau reduction as compelling and potentially superior to other blood-brain barrier platforms.

Oct 14, 2026·4 sources
00
Sep 29, 2026

UniQure's Huntington's gene therapy shows weaker benefit after four years

UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.

Sep 29, 2026·3 sources
00
Sep 21, 2026

FDA approves IntraBio's AQNEURSA as first treatment for ataxia-telangiectasia

The U.S. FDA has approved AQNEURSA (levacetylleucine) as the first and only approved treatment for ataxia-telangiectasia (A-T) in the United States or anywhere in the world. This marks the second FDA-approved indication for AQNEURSA.

Sep 21, 2026·2 sources
00
Sep 17, 2026

FDA approves Ultragenyx's Fayuvi, first gene therapy for Sanfilippo syndrome type A

The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.

Sep 17, 2026·4 sources
00
Aug 25, 2026

At least 25% of former NFL players who died between 2016-2021 had CTE, study finds

A new study examining former NFL players who died recently found that at least one in four had chronic traumatic encephalopathy (CTE), the brain disease long linked to repeated head impacts in football.

Aug 25, 2026·2 sources
00
Jun 15, 2026

Brain implant enables ALS patient to communicate for nearly two years, generating 2 million words

Casey Harrell, a 42-year-old man with ALS who lost his ability to speak, has successfully used a brain-computer interface for almost three years to communicate and control his computer, producing approximately 2 million words. The at-home brain implant represents a significant milestone in assistive technology for neurodegenerative disease patients.

Jun 15, 2026·3 sources
00
May 4, 2026

Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial

Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.

May 4, 2026·1 source
00
Apr 20, 2026

Gut Microbiome Analysis Can Predict Parkinson's Disease Risk Before Symptoms Appear

New research led by University College London shows that analysis of gut microbes can reveal elevated Parkinson's disease risk before any symptoms develop, offering potential for early intervention.

Apr 20, 2026·1 source
00

Top claims

  • ▪London-based Oyster Therapeutics raised $60 million in Series A-2 funding to advance its preclinical brain-penetrating small molecule degrader research in Alzheimer's disease
  • ▪Biogen reported preliminary Phase 2 data in May 2026 showing tau reduction and cognitive benefit for its antisense oligonucleotide diranersen, though the trial missed its main dose-response goal at week 76
  • ▪Oyster Therapeutics' $60 million Series A-2 round was led by 4BIO Capital, with participation from new investors Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures

Subtopics

Drug Policy, Pricing & Approval9Drug Approval and Clinical Trials6Alzheimer’s & dementia5Clinical trials4Gene therapy4Alzheimer's disease3FDA drug approval3Biotech innovation2Brain health & dementia researchers2Drug development2Drug discovery2Longevity & biohacking2Medical research2Accelerated approval pathways1Age related cognitive decline1Assistive technology.1Biomarkers & bloodwork testing1Biotech startup1Biotechnology1Brain-computer interfaces1Clinical Genomics & Genetics1Diet & nutrition1Drug safety1Eli Lilly1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories